Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Roferon-A for chronic hepatitis C labeling recommends 12-month treatment schedule.

Executive Summary

ROCHE ROFERON-A 12-MONTH TREATMENT REGIMEN FOR CHRONIC HEPATITIS C is recommended in product labeling. "Normalization of serum [alamine transaminose] ALT generally occurs within a few weeks after initiation of treatment in responders," labeling states. "Approximately 90% of patients who respond to Roferon-A do so within the first three months of treatment; however, patients responding with a reduction in ALT should complete 12 months of treatment." Schering-Plough's Intron-A labeling recommends that hepatitis C patients complete six months of therapy, but notes that optimal dose and duration are under investigation.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029194

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel